Quick Answer
Altimmune, Inc. reported Operating Income of -$94.49 million for fiscal year 2025.
Altimmune, Inc. Operating Income — Annual History
| Fiscal Year | Operating Income | YoY Change |
|---|---|---|
| 2025 | -$94.49M | +8.4% |
| 2024 | -$103.17M | -7.6% |
| 2023 | -$95.93M | -9.3% |
| 2022 | -$87.74M | +9.5% |
| 2021 | -$96.91M | -76.9% |
| 2020 | -$54.80M | -155.3% |
| 2019 | -$21.46M | +49.9% |
| 2018 | -$42.83M | +17.7% |
| 2017 | -$52.05M | -369.2% |
| 2016 | -$11.09M | -226.0% |
| 2015 | -$3.40M | +66.6% |
| 2014 | -$10.19M | +6.0% |
| 2013 | -$10.84M | -73.0% |
| 2012 | -$6.27M | +46.6% |
| 2011 | -$11.73M | +50.2% |
| 2010 | -$23.55M | — |
Quarterly Operating Income
| Quarter Ending | Operating Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$20.86M | +15.8% | +9.0% |
| June 30, 2025 | -$22.92M | +14.3% | -5.1% |
| March 31, 2025 | -$21.82M | +18.6% | +11.9% |
| September 30, 2024 | -$24.77M | -9.9% | +7.4% |
| June 30, 2024 | -$26.75M | -48.5% | +0.2% |
| March 31, 2024 | -$26.79M | -23.1% | -18.9% |
| September 30, 2023 | -$22.54M | +8.9% | -25.2% |
| June 30, 2023 | -$18.01M | +11.7% | +17.2% |
- Altimmune, Inc. showed an increase of +8.4% in Operating Income compared to the prior fiscal year.
- Over the 2010–2025 period, Altimmune, Inc.’s operating income has declined by 301.2% (from -$23.55 million to -$94.49 million).
- The most recent figure is from Altimmune, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 6, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: